乳腺癌患者血清抵抗素及Hs-CRP检测临床意义.docVIP

乳腺癌患者血清抵抗素及Hs-CRP检测临床意义【摘要】目的 探讨乳腺癌患者血清抵抗素和高敏C反应蛋白(Hs-CRP)含量的变化及其临床意义#65377;方法 选择病理确诊的乳腺癌住院患者77例(转移者53例#65380;未转移者24例)#65380;乳腺增生组40例和健康对照组36例作为对照组,术前抽取空腹静脉血并取血清,ELISA法测定血清抵抗素含量,以及采用免疫比浊法对血Hs-CRP进行测定#65377;结果 乳腺癌转移患者血清抵抗素和Hs-CRP含量明显高于未转移患者、乳腺增生患者以及健康对照组血清中的含量;同时乳腺癌患者TNM分期 II #65380; III、IV期血清抵抗素和Hs-CRP含量均高于I期血清抵抗素和Hs-CRP含量 (P0.05)结论 乳腺癌患者血清抵抗素和Hs-CRP含量升高,抵抗素和Hs-CRP含量的升高程度在预测乳腺癌转移和预后方面具有指导意义#65377; 【关键词】乳腺癌抵抗素高敏C反应蛋白 中国图分类号:R730.26文献标识码:A 文章编号:1005-0515(2010)08-066-03 The clinical significance of determination of resistin and high-sensitive C-reactive protein for the patients of breast cancer. 【Abstract】ObjectiveTo explore the clinical significance of determination of resistin and Hs-CRPfor the patients of breast cancer. MethodsAccording to metastasis of carcinoma or not, 77 patients of breast cancer who were diagnosed by pathology were divided into the metastasis group with 53 patients and the no-metastasis group with 24 patients, 36 normal women were control group. The fasting venous blood was taken from all subjects. And serum resistin concentrations was determined with enzyme linked immunosorbent assay (ELISA), Hs-CRP was determined by rate nephelometry immunoassay. ResultsSerum resistin concentrations in the metastasis group (2.70±1.50mg/L) were lower than those in the no-metastasis group (4.51±1.98mg/L)(P0.05). ConclusionSerum resistin concentrations in patients of breast cancer were lower than in normal women, and the serum resistin stepping down may predict metastasis and prognosis of breast cancer. 【Keywords】Breast cancerResistinHigh-sensitive C-reactive protein(Hs-CRP) 乳腺癌是女性最常见的恶性肿瘤,发病率为10%～15%[1]。近年来我国乳腺癌的发病率明显上升,从20世纪90年代初期就已成为女性中的第一位恶性肿瘤,乳腺癌的发病年龄以40～60岁的女性为最多见。抵抗素(Resistin)是白色脂肪细胞分泌的细胞因子,这种细胞因子不仅对调节胰岛素敏感性和糖脂代谢发挥着重要作用,参与了肥胖和高胰岛素血症的发生发展,近期研究表明还与乳腺癌的发生发展密切相关[2]#65377;本文通过检测乳腺癌患者血清抵抗素和高敏C反应蛋白(Hs-CRP)含量,以了解乳腺癌患者血清抵抗素和Hs-CRP含量的变化及其临床意义#65377; 1..临床资料 1.1..观察对象选择绝经后女性,按照有无淋巴结转移分为乳腺癌转移组和未转移组#65377;转移组53例患者,年龄49～68岁,平均56.2±4.2岁#65377;未